The FDA has Extended Approval of Zejula for Ovarian Cancer Patients With and Without BRCA Mutations
GlaxoSmithKline (GSK) has just announced that Zejula, otherwise known as niraparib, has just been approved for cancer patients beyond those who have a BRCA+ mutation. The patients now included in…